Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8410428 | 0.82 | ALDH1A1 (0.44) | SLC22A12ALDH1A1 | |
| SCHEMBL244815 | 0.78 | EPHX1 (0.52) | IDO1ALDH1A1 | |
| SCHEMBL14730465 | 0.78 | GRM4 (0.48) | SLC22A12GRM4BLMWRNALDH1A1 | |
| SCHEMBL8410029 | 0.78 | SLC22A12 (0.51) | SLC22A12GRM4IDO1VCAM1BLM | |
| SCHEMBL8343255 | 0.77 | SLC22A12 (0.50) | SLC22A12GRM4IDO1VCAM1BLM | |
| SCHEMBL3833327 | 0.77 | SLC22A12 (0.50) | SLC22A12GRM4IDO1VCAM1BLM | |
| SCHEMBL546977 | 0.75 | SLC22A12 (0.56) | SLC22A12 | |
| SCHEMBL5519988 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL4549089 | 0.74 | VCAM1 (0.46) | SLC22A12GRM4IDO1VCAM1BLM | |
| SCHEMBL25024871 | 0.74 | ABCG2 (0.43) | SLC22A12BLMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
| WO-2023078231-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-11 | — | — | WO | disclosed |
| EP-0718277-B1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO LTD (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0718277-A1 | Method for producing 5-substituted-2-acylaminophenols, and 5-alkyl-2-acylaminophenol compound and N-acyl-N-(4-alkyl-phenyl)hydroxylamine compound | FUJI PHOTO FILM CO., LTD. (JP) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | SLC22A12 3820/4885GRM4 2776/4885IDO1 1505/4885 |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | SLC22A12 3820/4885GRM4 2776/4885IDO1 1505/4885 |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | ACE2, ACE, SARS1 | SLC22A12 3820/4885GRM4 2776/4885IDO1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.